Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing therapies for fibrotic disease and cancer by targeting galectin proteins, particularly galectin-3. Its lead drug candidate, belapectin (GR-MD-02), is a patented, plant-derived complex carbohydrate compound being developed for MASH cirrhosis (prevention of esophageal varices) and head and neck squamous cell carcinoma. The company completed its Phase 2b/3 NAVIGATE trial in 2024 and also conducts small molecule galectin-3 inhibitor research through its majority-owned subsidiary, Galectin Sciences LLC.
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001140361-26-012155 | EDGAR | 63K words |
| 2025-03-31 | 2024-12-31 | 0001140361-25-011169 | EDGAR | 64K words |
| 2024-03-29 | 2023-12-31 | 0001140361-24-016452 | EDGAR | 60K words |
| 2023-03-30 | 2022-12-31 | 0001140361-23-014658 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001140361-22-012058 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001193125-21-101402 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001193125-20-073907 | EDGAR | — |
| 2019-03-06 | 2018-12-31 | 0001193125-19-064705 | EDGAR | — |
| 2018-03-29 | 2017-12-31 | 0001193125-18-100592 | EDGAR | — |
| 2017-03-28 | 2016-12-31 | 0001193125-17-098753 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001140361-26-032945 | EDGAR | 25K words |
| 2025-11-14 | 2025-09-30 | 0001140361-25-042116 | EDGAR | 24K words |
| 2025-08-14 | 2025-06-30 | 0001140361-25-031039 | EDGAR | 24K words |
| 2025-05-15 | 2025-03-31 | 0001140361-25-019149 | EDGAR | 21K words |
| 2024-11-14 | 2024-09-30 | 0001140361-24-046726 | EDGAR | 22K words |
| 2024-08-13 | 2024-06-30 | 0001140361-24-036937 | EDGAR | 21K words |
| 2024-05-15 | 2024-03-31 | 0001140361-24-026105 | EDGAR | 18K words |
| 2023-11-13 | 2023-09-30 | 0001140361-23-052729 | EDGAR | 20K words |
| 2023-08-14 | 2023-06-30 | 0001140361-23-039411 | EDGAR | 19K words |
| 2023-05-15 | 2023-03-31 | 0001140361-23-024499 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001140361-22-041167 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001140361-22-029555 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-14 | 0001140361-26-032946 | EDGAR | 2K words |
| 2026-08-04 | 0001140361-26-031058 | EDGAR | 1K words |
| 2026-03-31 | 0001140361-26-012158 | EDGAR | 2K words |
| 2026-03-17 | 0001140361-26-009735 | EDGAR | 1K words |
| 2026-01-21 | 0001140361-26-001866 | EDGAR | 1K words |
| 2026-01-12 | 0001140361-26-000994 | EDGAR | 0K words |
| 2025-12-19 | 0001140361-25-046115 | EDGAR | 1K words |
| 2025-12-08 | 0001140361-25-044711 | EDGAR | 1K words |
| 2025-12-03 | 0001140361-25-044148 | EDGAR | 2K words |
| 2025-11-14 | 0001140361-25-042118 | EDGAR | 2K words |
344 total filings indexed. 312 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001133416 |
| Ticker | GALT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Headquarters | Atlanta, GA (suburb) |
| Website | https://www.galectintherapeutics.com |
| Listed | 2002-09-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GALT (~200 tokens, structured JSON with cryptographic provenance)